ClinicalTrials.gg
RecruitingNCT07188025REACTUpdated Oct 2, 2026

ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

A Phase 3 interventional study of Adjuvant chemotherapy in Rectal Cancer, sponsored by Erasmus Medical Center. Recruiting at 25 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Erasmus Medical Center · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 2, 2026Site recruiting status changedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Rectal Neoplasms with a site in Netherlands — 21 open to participants now, 32 under way, 8 of them phase 3. Rectal Neoplasms · Netherlands.

Planned enrollment
32nd of 59
103 · median 108
Started
2025
with 5 others
Phase 3
19 of 74
4 open now
Primary completion
2030-10
later than 30 of 31 live
Registered
69th of 74
by date

Among the 74 studies in Rectal Neoplasms with a site in Netherlands, this one is the 32nd largest by planned enrollment of the 59 interventional ones that give a count, is one of 6 that started in 2025, is one of 19 in phase 3, reaches primary completion later than 30 of the 31 other live ones, and was the 69th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

21 of the 74 studies in Rectal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Rectal Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery.

The main research question the REACT study aims to answer is:

- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery?

Interventions:

- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX/6 cycles FOLFOX) within 12 weeks after surgery.

Read the detailed description

Rationale - Rectal cancer is a worldwide cause of cancer related mortality. The incidence of rectal cancer in the Netherlands is approximately 3500 patients per year. The introduction of combined neoadjuvant (chemo)radiotherapy and total mesorectal excision (TME) has significantly reduced the local recurrence rate, but distant recurrence rates remain around 30%. Recurrences are likely to derive from residual local disease or subclinical metastatic disease (minimal residual disease). These micro metastases are undetectable by the currently used imaging techniques but still present after surgery. Adjuvant chemotherapy might be beneficial for patients at high risk for recurrence. However, there are only a few randomised controlled trials on perioperative chemotherapy available. Studies on adjuvant chemotherapy in rectal cancer yielded conflicting results. As a consequence, treatment with adjuvant chemotherapy in patients with rectal cancer is not evidence based and therefore not standard of care in the Netherlands. Recent studies suggest that preoperative intensive chemotherapy with radiotherapy, compared to standard chemotherapy and radiotherapy, resulted in a prolonged disease-free survival and overall survival. However, this was at the cost of increased toxicity, and whether the observed improvement in overall survival can be attributed to the addition of neo-adjuvant intensive chemotherapy is under debate. Consequently, there is an urgent need for biomarkers to identify those patients at high risk to recur after standard treatment, to select the patients that might benefit the most from adjuvant chemotherapy.

Objective - To investigate disease-free survival in patients with high-risk rectal cancer by treating these patients with adjuvant chemotherapy in case of detectable ctDNA after surgery.

Main trial endpoints - The primary endpoint of the study will be disease-free survival in the intention-to-treat population, calculated from the date of surgery to the date of recurrence or death from any cause of the patient, whichever occurs first.

Secondary trial endpoints - Secondary outcomes will be disease-free survival, carried out as per protocol analysis to analyse pure treatment effect. In addition, overall survival will be calculated measured from the date of surgery to the date of death from any cause. Quality of life will be assessed in both groups by obtaining already completed questionnaires provided by the PLCRC cohort study to compare the effect of adjuvant chemotherapy on quality of life. The robustness of ctDNA as biomarker will be analysed by comparing the disease-free survival of patients with detectable ctDNA who are not treated adjuvant chemotherapy (control group) with patients with undetectable ctDNA. The clearance of ctDNA of the patients who received adjuvant chemotherapy in the experimental group will be compared with the patients in the control group. Lastly, the co-occurrence of ctDNA in peripheral blood at the timing of detection of recurrent disease on imaging will be studied.

Trial design - The proposed study is conducted within the prospective Dutch ColoRectal Cancer (PLCRC) cohort and follows the trial within cohort (TwiCs) design, i.e. a randomised controlled trial within a prospective cohort.

Trial population - Patients ≥ 18 years of age with primary resected rectal cancer that meet the inclusion criteria, participating in the PLCRC cohort with informed consent for randomisation and considered physically fit for adjuvant chemotherapy are eligible.

Interventions - Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy within 8 weeks of surgery and no longer than 12 weeks after surgery. Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX). Duration of treatment will be 3 months (12 weeks).

Ethical considerations - In current clinical practice there is no indication for adjuvant chemotherapy for patients after surgery for primary rectal cancer. Therefore, all participating patients have no indication for adjuvant chemotherapy. Patients randomised to the experimental group will be offered adjuvant chemotherapy to reduce recurrence. According to routine clinical care, patients receiving adjuvant chemotherapy will undergo blood withdrawals and visit their treating physician before every cycle of chemotherapy. The combination chemotherapy schedule of CAPOX and FOLFOX is commonly administered in the adjuvant setting in current practice for colorectal cancer, therefore the risks and toxicity of the used adjuvant chemotherapy are well-known. The majority of side-effects are manageable and transient. The risk of the withdrawal of extra tubes of blood during regular blood withdrawal in all study participants is negligible. The benefit for participants enrolled in this trial is the potential chance to reduce their risk of recurrence with adjuvant chemotherapy.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • ctDNA
  • Adjuvant Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Detectable ctDNA in the postoperative blood sample
  • Age ≥ 18 years
  • WHO performance score 0-1
  • for PLCRC with specific consent for additional blood withdrawals and offering of future experimental research
  • Informed consent for the REACT trial.
  • Histological confirmed rectal cancer; either treated with (chemo)radiotherapy, and/or clinical/pathological T3/T4 and/or N+ in case no neoadjuvant therapy was administered.
  • Eligible to receive treatment with combination adjuvant chemotherapy (CAPOX/FOLFOX) according to the treating physician.
  • Mentally competent and able to read and understand Dutch language.

Exclusion criteria

Exclusion Criteria:

  • disease
  • Another in previous 5 years, with the exception of treated carcinoma in situ or skin cancer other than melanoma
  • Incomplete primary tumour resection (R1 or R2 resection)
  • for fluoropyrimidines or oxaliplatin
  • oxaliplatin based systemic treatment, e.g. treated with the RAPIDO regimen consisting of short course radiotherapy followed by 6 cycles of CAPOX or 9 cycles of FOLFOX prior to surgery
  • Patients with a clinical complete response, who will not undergo surgery.
  • Pregnant and lactating women
  • History of psychiatric disability judged by the investigator to be , precluding or interfering with compliance of the intervention group
  • Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator
  • Serious infections (uncontrolled or requiring treatment)
  • Current or recent (within 28 days prior to randomisation) treatment with another drug or participation in another study interfering with the primary endpoint.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (estimated)

Study arms

  • No intervention
    Standard of Care

    Control group ctDNA+

  • Experimental
    Adjuvant chemotherapy

    Intervention group ctDNA+

    Drug: Adjuvant chemotherapy

Interventions

  • DrugAdjuvant chemotherapy

    Adjuvant chemotherapy consists of 6 cycles of 5FU/folinic acid and oxaliplatin (FOLFOX) every 2 weeks, or 4 cycles of capecitabine and oxaliplatin (CAPOX). Duration of treatment will be 3 months (12 weeks).

06

What researchers measure

Primary outcomes

  1. Disease-free survival, intention-to-treat

    To investigate whether the disease-free survival in patients with rectal cancer who have detectable ctDNA after primary tumour resection, can be improved by administration of adjuvant chemotherapy.

    Time frame: Calculated from the date of surgery to the date of progression (recurrence) or death from any cause of the patient, whichever occurs first, assessed up to 2 years of follow-up

Secondary outcomes

  1. Overall survival, intention-to-treat

    To investigate whether overall survival of rectal cancer patients with detectable ctDNA after surgery can be improved with adjuvant chemotherapy

    Time frame: From the date of surgery to the date of death from any cause of the patient, with a median follow-up of 5 years

  2. Disease-free survival, per-protocol

    To compare all (eligible) patients in the control group to patients in the experimental group who actually started the adjuvant chemotherapy by a per protocol analysis (for pure treatment effect) for disease-free survival.

    Time frame: Calculated from the date of surgery to the date of progression (recurrence) or death from any cause of the patient, assessed up to 2 years of follow-up

  3. Overall survival, per-protocol

    To compare all (eligible) patients in the control group to patients in the experimental group who actually started the adjuvant chemotherapy by a per protocol analysis (for pure treatment effect) for overall survival.

    Time frame: Calculated from the date of surgery to the date of death from any cause of the patient, with a median follow-up of 5 years

  4. The effect of adjuvant chemotherapy on quality of life - EQ-5D-5L

    To compare the effect of adjuvant chemotherapy on quality of life - EQ-5D-5L

    Time frame: Questionnaires are obtained within PLCRC at baseline, 3 months, 6 months, 1 year, 1.5 years, 2 years and yearly after, assessed up to 4 years of follow-up

  5. The effect of adjuvant chemotherapy on quality of life - QLQ-C30

    To compare the effect of adjuvant chemotherapy on quality of life - QLQ-C30

    Time frame: Questionnaires are obtained within PLCRC at baseline, 3 months, 6 months, 1 year, 1.5 years, 2 years and yearly after, assessed up to 4 years of follow-up

  6. The effect of adjuvant chemotherapy on quality of life - QLQ-CR29

    To compare the effect of adjuvant chemotherapy on quality of life - QLQ-CR29

    Time frame: Questionnaires are obtained within PLCRC at baseline, 3 months, 6 months, 1 year, 1.5 years, 2 years and yearly after, assessed up to 4 years of follow-up

  7. Comparing disease-free survival of patients with detectable ctDNA but without receiving adjuvant chemotherapy with patients with undetectable ctDNA

    The disease-free survival of ctDNA negative patients will be collected and analysed to confirm the robustness of postoperative ctDNA as biomarker in rectal cancer.

    Time frame: Calculated from the date of surgery to the date of progression (recurrence) or death from any cause of the patient, assessed up to 2 years of follow-up

  8. Comparing overall survival of patients with detectable ctDNA but without receiving adjuvant chemotherapy with patients with undetectable ctDNA

    Overall survival of ctDNA negative patients will be collected and analysed to confirm the robustness of postoperative ctDNA as biomarker in rectal cancer.

    Time frame: Calculated from the date of surgery to the date of death from any cause of the patient, with a median follow-up of five years

  9. To investigate the prognostic value of ctDNA clearance after adjuvant chemotherapy

    The disease-free survival and overall survival of the patients who had clearance of ctDNA after adjuvant chemotherapy will be compared with the patients who did not clear the ctDNA after adjuvant chemotherapy.

    Time frame: Two 10 mL CellSave blood samples will be collected at least 14 days after completion of chemotherapy. ctDNA clearance (yes/no) will be analyzed for correlation with disease-free survival at 2 years and overall survival at 5 years.

  10. To investigate the co-occurrence of ctDNA in peripheral blood at the timing of detection of recurrent disease on imaging.

    Of all patients who underwent post-operative blood sampling for ctDNA screening, the proportion of patients with detectable ctDNA in the peripheral blood at the timing of detection of recurrent disease on imaging will be assessed.

    Time frame: Up to 2 years after rectal surgery, at the time recurrent disease is detected on imaging and prior to any additional treatments.

Other outcomes

  1. The proportion of ctDNA-positive patients with specific mutational profiles.

    To determine the mutational profile and ctDNA levels in ctDNA-positive patients.

    Time frame: Assessed from the blood sample taken 14-28 days after rectal surgery.

  2. Correlations between ctDNA mutational profiles and clinical/pathological parameters and time to recurrence

    To identify and analyse specific mutations detected in ctDNA and their correlation with clinical and pathological parameters, as well as time to recurrence.

    Time frame: Assessed from the blood sample taken 14-28 days after rectal surgery.

  3. Concordance rate (%) between mutations identified in ctDNA and matched tumour tissue

    To compare the mutational status of ctDNA with the mutational profile of available tumour tissue in patients, assessing concordance and potential discrepancies.

    Time frame: Assessed from the blood sample taken 14-28 days after rectal surgery.

07

Study locations

20 of 25 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2030, 60 months after the start.

Of 73 non-industry phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 104. This study's planned 60 months is below that.

Counting every sponsor, half of 81 studies reached it within 59 months; a quarter within 37 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 23, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2035
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (5 now recruiting)
Show 5 sites
  • Amsterdam UMC · Amsterdam, NetherlandsNot yet recruiting→Recruiting
  • Catharina Ziekenhuis · Eindhoven, NetherlandsNot yet recruiting→Recruiting
  • Antonius Ziekenhuis Sneek · Sneek, NetherlandsNot yet recruiting→Recruiting
  • Haaglanden Medisch Centrum · The Hague, NetherlandsNot yet recruiting→Recruiting
  • Bernhoven · Uden, NetherlandsNot yet recruiting→Recruiting
Oct 2, 2026
Sponsor
Collaborators added: Dutch Colorectal Cancer Group; collaborators removed: Dutch Colorectal Cancer Group (DCCG)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Amsterdam UMC · Amsterdam, NetherlandsNot yet recruiting→Recruiting
    • Catharina Ziekenhuis · Eindhoven, NetherlandsNot yet recruiting→Recruiting
    • Antonius Ziekenhuis Sneek · Sneek, NetherlandsNot yet recruiting→Recruiting
    • Haaglanden Medisch Centrum · The Hague, NetherlandsNot yet recruiting→Recruiting
    • Bernhoven · Uden, NetherlandsNot yet recruiting→Recruiting
    Sponsor Collaborators added: Dutch Colorectal Cancer Group; collaborators removed: Dutch Colorectal Cancer Group (DCCG)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07188025
Collaborators
Prospectief Landelijk CRC Cohort (PLCRC), Dutch Colorectal Cancer Group, BOOG Study Center
Responsible party
Mirthe Ubink (MD, Erasmus Medical Center) — Principal investigator
First posted
Sep 23, 2025
Start date
Oct 14, 2025
Primary completion
Oct 2030 (estimated)
Completion
Oct 2035 (estimated)
Last update
Oct 2, 2026

Study contacts

Mirthe Ubink, MD
Contact
REACT@erasmusmc.nl
+31650162308
Cornelis Verhoef, MD, PhD
Contact
0031 10 704 1902
Cornelis Verhoef, MD, PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion